1. Short title This Act may be cited as the Mapping America's Pharmaceutical Supply Act or the MAPS Act . 2. Federal U.S. pharmaceutical supply chain mapping (a) In general The Secretary of Health and Human Services, in coordination with the heads of other relevant agencies, including the Secretary of Defense and the Secretary of Homeland Security, shall support efforts, including through public-private partnerships, to map the entire United States pharmaceutical supply chain, from inception to distribution, and use data analytics to identify supply chain vulnerabilities and other national security threats. Such activities shall include, at minimum— (1) defining agency roles in monitoring the pharmaceutical supply chain and communicating supply chain vulnerabilities; (2) establishing a database of drugs selected from the essential medicines list developed by the Food and Drug Administration in response to Executive Order 13944 (85 Fed. Reg. 49929) and any other relevant assessments or lists, as appropriate, to identify, in coordination with the private sector, a list of essential medicines, to be updated regularly and published on a timeframe that the Secretary of Health and Human Services, in coordination with the Secretary of Defense and the Secretary of Homeland Security, determines appropriate, which shall include the drugs and the active pharmaceutical ingredients of such drugs that— (A) are reasonably likely to be required to respond to a public health emergency or to a chemical, biological, radiological, or nuclear threat; or (B) the shortage of which would pose a significant threat to the United States health care system or at-risk populations